Dr Steve Conlan
Co-Director Centre for NanoHealth, Swansea University.

Steve Conlan is a Senior Lecturer in Cell and Molecular Biology in the Reproductive Biology Group at the School of Medicine, Swansea University, where he also leads the School's activities in NanoHealth.

He completed his PhD in 1994 at the University of London before undertaking postdoctoral research at the John Innes Centre in Norwich and then IMBB-FORTH in Crete, Greece. In 2000, he returned to Swansea University to take up a lectureship in the Department of Genetics and, in 2005, moved into the School of Medicine. He works closely with colleagues in the adjacent Singleton Hospital, part of the recently formed Abertawe Bro Morgannwg University NHS Trust, to develop projects that address immediate clinical need.

Steve's main area of interest is in the regulation of gene expression in both model eukaryote systems and human health. Research undertaken in the Reproductive Biology Group focuses on understanding infertility and gynaecological cancer due to abnormalities in the endometrium (the lining of the womb) through investigation of the impact of aberrant transcription processes. The aim of the group is to work towards biomarkers and points of intervention that can be developed for clinical use.

In 2002, together with colleagues in Swansea University's School of Engineering, Steve initiated the *Nanotechnology for Healthcare - NanoHealth* research programme at the University, where biomedical scientists, clinicians, engineers and physicists, as well as academics from other disciplines, continue to develop interdisciplinary research projects. He is Co-Director of the £22 Million Centre for NanoHealth at Swansea University, which is focused on the development of novel sensors and devices though partnerships with the healthcare industry.

Steve is interested in a wide range of developments within NanoHealth, including ultra-high resolution imaging of protein complexes to understand transcription function, characterising cellular interactions at the nanoscale, the development of biosensors and devices based on nanoelectronics and the printing of biomaterials and cells, as well as the development of hybrid molecules for the targeted regulation of gene expression.

His experience extends to the management of collaborative projects with industry in the UK, Belgium and the US.

Steve is also instrumental in Swansea University's participation in the Texas – United Kingdom Collaborative, where he leads collaborative ventures in healthcare for the School of Medicine with both Academic and Industrial US based partners.